Allos Therapeutics, Inc.
11080 Circlepoint Road
Suite 200
Westminster,
CO 80020
United States - Map
Phone: 303-426-6262
Fax: 303-412-9160
Web Site: http://www.allos.com
| Allos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule therapeutics for the treatment of cancer. Its lead product candidate, PDX (pralatrexate), is a novel antifolate under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. Its other product candidate is RH1, a targeted chemotherapeutic agent, under evaluation in Phase 1 in patients with advanced solid tumors or non-Hodgkin's Lymphoma. Allos Therapeutics was founded in 1992. It was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in 1994. The company is headquartered in Westminster, Colorado. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Paul Berns , 41
Chief Exec. Officer, Pres and Exec. Director |
$
753.00K | N/A | Mr. David C. Clark , 39
Chief Financial Officer, Principal Accounting Officer, VP of Fin., Treasurer and Assistant Sec. |
$
242.00K | N/A | Dr. Pablo J. Cagnoni M.D., 45
Chief Medical Officer and Sr. VP |
N/A
| N/A | Mr. Marc H. Graboyes , 38
Sr. VP, Sec., Gen. Counsel and Member of Management Team |
$
325.00K | N/A | Mr. James V. Caruso , 49
Chief Commercial Officer and Exec. VP |
$
532.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.49% Nasdaq 
0.27%
Profile
